text:
Join the 'Sustiva' group to help and get support from people like you.
Sustiva News
Black Americans Still Undertreated for HIV
Posted 3 Feb 2017 by Drugs.com
FRIDAY, Feb. 3, 2017 – Although progress has been made, blacks in America are still being hit harder by HIV/AIDS, a new report from the U.S. Centers for Disease Control and Prevention says. The CDC study found that of more than 12,200 black men and women diagnosed with HIV in 2014, nearly 22 percent had progressed to AIDS by the time they were diagnosed. That means diagnosis and treatment is often coming too late. Moreover, among all black Americans with HIV in 2013, only about 54 percent were receiving continuous medical care. Of those getting care, less than half had effectively suppressed the virus. This is far below the National HIV/AIDS Strategy goals of 90 percent of HIV patients in treatment and 80 percent with undetectable HIV by 2020, the study authors noted. "While we have made great progress in HIV prevention among African Americans in recent years, it is clear that we need ... Read more
Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Truvada, Famciclovir, Baraclude, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Valcyte, Entecavir, Copegus
Diabetes Risk May Be Higher for HIV-Positive Adults
Posted 31 Jan 2017 by Drugs.com
TUESDAY, Jan. 31, 2017 – People infected with the virus that causes AIDS may be more likely to develop diabetes, new research suggests. In the study, the prevalence of diabetes was almost 4 percent higher among HIV-positive adults than the general population. Researchers examined survey responses of 8,610 HIV-positive participants in the Medical Monitoring Project (MMP). They also analyzed data from about 5,600 people in the general public who took the annual National Health and Nutrition Examination Survey (NHANES). Of the MMP participants, 75 percent were men and nearly 60 percent were aged 45 or older. About 25 percent were obese; about 20 percent also had hepatitis C (HCV); and 90 percent had received antiretroviral therapy within the past year. Of NHANES participants, about half were men aged 45 years and older; 36 percent were obese; and fewer than 2 percent had hepatitis C. The ... Read more
Related support groups: Obesity, Diabetes, Type 2, Metformin, Insulin, Lantus, HIV Infection, Glucophage, Novolog, Glipizide, Humalog, Glyburide, Lantus Solostar, Levemir, Glimepiride, Pre-Exposure Prophylaxis, Incivek, Novolin R, Amaryl, Novolin N, Humulin N
Can HIV Drugs Boost Syphilis Risk?
Posted 17 Jan 2017 by Drugs.com
MONDAY, Jan. 16, 2017 – Gay and bisexual men taking antiretroviral drugs to treat HIV infection may be at increased risk for syphilis, new research contends. Based on a review of available evidence, the investigators concluded that the drugs may boost susceptibility to the bacterium that causes syphilis, although the study did not prove cause-and-effect. The finding might explain why new and repeat cases of syphilis in gay and bisexual men have risen sharply compared to other sexually transmitted infections over the past decade, the researchers wrote. The study team was led by Dr. Michael Rekart, from the University of British Columbia's School of Population and Public Health in Vancouver. The findings were published in the Jan. 16 issue of the journal Sexually Transmitted Infections. The authors of an editorial that accompanied the study said the theory is "intriguing" and "warrants ... Read more
Related support groups: HIV Infection, Sexually Transmitted Diseases, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Syphilis, Famciclovir, Baraclude, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Tenofovir, Daklinza
Doctors Seeing More HIV Patients With Multidrug Resistance
Posted 1 Dec 2016 by Drugs.com
THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked with resistance to older drugs called thymidine analogues. Among patients whose HIV had this mutation, 80 percent were also resistant to tenofovir, the main drug in most modern HIV treatment and prevention programs, the researchers reported. The findings were published in the Nov. 30 issue of The Lancet Infectious Diseases journal. "We were very surprised to see that so many people were resistant to both drugs, as we didn't think this was possible," study lead author Ravi Gupta, of University ... Read more
Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Epclusa, Zepatier, Baraclude, Genvoya, Victrelis, Sofosbuvir, Viread, Kaletra, Viekira Pak, Norvir
Antibodies May Hold Key to HIV Suppression
Posted 10 Nov 2016 by Drugs.com
WEDNESDAY, Nov. 9, 2016 – Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions of an anti-HIV antibody known as VRC01. The antibody was safe and repressed blood levels of HIV for a short time before the virus reappeared, the researchers said. HIV is the virus that can lead to AIDS. "We were not expecting that we were going to see a prolonged repression, because it was only a single antibody," said co-study author Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. The next phase is to infuse two or three antibodies intermittently, and see if antiretroviral drugs can be withdrawn permanently, he explained. After regular intravenous infusions of VRC01, participants in the U.S. National Institutes of ... Read more
Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Famciclovir, Baraclude, Victrelis, Famvir, Viread, Kaletra, Valcyte, Entecavir, Norvir, Copegus, Tenofovir, Ribasphere
HIV May Hide in Tissues, Even After Treatment
Posted 27 Oct 2016 by Drugs.com
WEDNESDAY, Oct. 26, 2016 – HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV in the blood and controls the disease. But the new findings suggest that HIV in the tissues may not cause AIDS but could contribute to the development of unrelated conditions, such as cancer and heart disease, according to the University of California, San Francisco (UCSF) researchers. "Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals," said study senior author Dr. Michael McGrath. "Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications," said McGrath. He is UCSF professor of laboratory medicine at the AIDS and Cancer ... Read more
Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Sovaldi, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Famciclovir, Baraclude, Victrelis, Sofosbuvir, Famvir, Viread, Kaletra, Valcyte, Copegus, Norvir, Tenofovir
Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis
Posted 26 Oct 2016 by Drugs.com
WEDNESDAY, Oct. 26, 2016 – Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already debunked by the research: That there was a "Patient Zero" who somehow caused the epidemic of human immunodeficiency virus (HIV) in the United States. "In many ways, the historical evidence has been pointing to the fallacy of Patient Zero for decades," said Dr. Richard McKay, who studies the history behind the AIDS epidemic and was a co-author on the new study. "We now have additional [genetic] evidence that helps to consolidate this position," McKay said in a news release from the University of Cambridge in England. He is a professor in the university's departments of history and philosophy of science. The new genetic research was published Oct. 26 in the journal ... Read more
Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Viread, Kaletra, Tenofovir, Entecavir, Norvir, Telaprevir, Lamivudine, Nevirapine, Boceprevir, Reyataz, Prezista, Diagnosis and Investigation, Lexiva, Norvir Soft Gelatin, Hepsera, Abacavir
Monkey Study Hints at Drug-Free Suppression of HIV
Posted 13 Oct 2016 by Drugs.com
THURSDAY, Oct. 13, 2016 – Scientists may have found a way to suppress an HIV-like infection in monkeys, without the need for ongoing drug therapy. The researchers added antibody therapy to standard drug treatment given to macaque monkeys infected with simian immunodeficiency virus (SIV). After three months, the animals were taken off the drugs, but their viral levels remained low to undetectable – for close to two years. Experts stressed that the animal findings need to be viewed with caution, and that many questions remain. But, they were also hopeful this could lead to a therapy that frees at least some people from their HIV drug regimens. An initial safety study has already started at the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The drug "cocktails" used to treat HIV – known as combined antiretroviral therapy (ART) – have changed the face of the ... Read more
Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Incivek, Zovirax, Famciclovir, Baraclude, Victrelis, Famvir, Viread, Kaletra, Tenofovir, Entecavir, Ribasphere, Copegus, Valcyte, Norvir, Telaprevir
Mixed Progress in Worldwide Fight Against HIV/AIDS
Posted 19 Jul 2016 by Drugs.com
TUESDAY, July 19, 2016 – The number of HIV/AIDS deaths worldwide each year has fallen since peaking in 2005, but the number of new HIV infections is up in 74 countries, according to a new study. Deaths from HIV/AIDS fell to 1.2 million in 2015 from 1.8 million in 2005. Though the number of new HIV infections has decreased since a peak of 3.3 million in 1997, it has been relatively stable at about 2.5 million a year for the past decade. Worldwide, new HIV infections fell just 0.7 percent a year between 2005 and 2015, compared to 2.7 percent a year between 1997 and 2005, the study found. Sub-Saharan Africa continued to be a trouble spot, accounting for three-quarters of new HIV infections (1.8 million) in 2015. Last year, south Asia had 8.5 percent (212,500) of new infections; southeast Asia, 4.7 percent (117,500); and east Asia, 2.3 percent (57,500). Between 2005 and 2015, the ... Read more
Related support groups: Infections, HIV Infection, Tamiflu, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Oseltamivir, Viread, Kaletra, Entecavir, Norvir, Tenofovir, Lamivudine, Telaprevir, Nevirapine, Boceprevir, Prezista, Reyataz, Abacavir
HIV Infection Seems to Affect Nervous System
Posted 13 Jun 2016 by Drugs.com
MONDAY, June 13, 2016 – Many newly infected HIV patients experience neurological problems, but they tend to be mild and they subside after antiretroviral drugs are given, a new study finds. "We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study author Dr. Joanna Hellmuth. She is a clinical fellow in the department of neurology at the University of California, San Francisco (UCSF). "While the findings were mild, it is clear that HIV affects the nervous system within days of infection," she said in a university news release. "Since the majority of these neurologic issues were resolved with treatment, our study reinforces recommendations that people at risk for HIV test often and start antiretroviral treatment immediately if they are infected," Hellmuth added. Among 139 people in Thailand infected with HIV three ... Read more
Related support groups: Peripheral Neuropathy, Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Autonomic Neuropathy, Zepatier, Genvoya, Baraclude, Victrelis, Viread, Kaletra, Viekira Pak, Daklinza, Entecavir
HIV Decline Falls Short of U.S. 5-Year Goal
Posted 6 May 2016 by Drugs.com
FRIDAY, May 6, 2016 – Although HIV infection and transmission rates in the United States declined over the past five years, they fell short of White House targets, a new study finds. Between 2010 and 2015, new HIV infections decreased 11 percent and transmission of the AIDS-causing virus declined 17 percent, far less than the goals set in 2010 as part of the U.S. National HIV/AIDS Strategy (NHAS), researchers said. The NHAS goals for 2015 were reductions of 25 percent for new HIV infections and 30 percent declines in HIV transmission. "Even though we missed the goals by a sizable margin, it's promising to see that we made important progress in reducing rates of HIV infection and transmission," said lead study author Robert Bonacci. He is a fourth-year medical student at the University of Pennsylvania Perelman School of Medicine. The aim was to lower the persistent HIV infection rate ... Read more
Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Zepatier, Baraclude, Genvoya, Victrelis, Viread, Viekira Pak, Kaletra, Entecavir, Tenofovir, Norvir, Lamivudine
People With HIV May Age Faster, Study Suggests
Posted 21 Apr 2016 by Drugs.com
THURSDAY, April 21, 2016 – People with HIV may age prematurely, putting them at increased risk for an earlier death, a new study indicates. With antiretroviral therapy, many people with HIV can expect to live for decades after being infected with the AIDS-causing virus. However, doctors have noted that these patients often show signs of premature aging. Using what they called a highly accurate marker for aging on a biological level, the study authors reported that HIV seems to cause an average of nearly five years of premature aging. This increases the risk of early death by 19 percent, according to the study published April 21 in the journal Molecular Cell. "The medical issues in treating people with HIV have changed," said study co-author Howard Fox, a professor in the department of pharmacology and experimental neuroscience at the University of Nebraska Medical Center in Omaha. ... Read more
Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Viread, Kaletra, Tenofovir, Norvir, Entecavir, Lamivudine, Telaprevir, Reyataz, Prezista, Nevirapine, Boceprevir, Lexiva, Norvir Soft Gelatin, Hepsera, Zidovudine
Prenatal Use of HIV Drug May Slow Child's Development Slightly
Posted 23 Feb 2016 by Drugs.com
TUESDAY, Feb. 23, 2016 – A drug used to prevent mother-to-child HIV transmission during pregnancy may slow language development slightly in children, a new study suggests. Researchers followed more than 900 infants who were born to HIV-positive mothers but were not infected by the AIDS-causing virus. All of the mothers took antiretroviral drugs during pregnancy. Some of the treatment regimens included a drug called atazanavir (Reyataz), while others did not. The infants underwent a standard test of development at 1 year of age. The 167 infants whose mothers took atazanavir during pregnancy had slightly lower language and social development scores than the 750 infants whose mothers did not take the drug. But the study only showed an association between atazanavir and language delays in children, and did not prove a cause-and-effect link. And the difference in social development scores ... Read more
Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Baraclude, Genvoya, Victrelis, Viread, Viekira Pak, Kaletra, Entecavir, Tenofovir, Norvir, Lamivudine, Telaprevir
Vaginal Ring Offers Some Protection Against HIV, Study Says
Posted 23 Feb 2016 by Drugs.com
MONDAY, Feb. 22, 2016 – An insertable vaginal ring containing a month's supply of a continuous-release HIV prevention drug reduced the risk of HIV in African women by at least 27 percent, a new study found. The ring works by slowly and continuously delivering a highly localized and controlled amount of the antiretroviral medication dapivirine. This drug aims to halt the ability of HIV – the virus that causes AIDS – to replicate inside a healthy cell. The goal: to prevent HIV infection, rather than treat it, the researchers said. "These results come after a number of challenging years in the effort to find ways to improve HIV control," said study lead author Dr. Jared Baeten, a professor in the departments of global health, medicine and epidemiology at the University of Washington in Seattle. "But while the dapivirine vaginal ring isn't commercially available yet, I'm really very ... Read more
Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Genvoya, Baraclude, Viral Infection, Victrelis, Viread, Kaletra, Viekira Pak, Tenofovir, Norvir, Entecavir, Lamivudine
Alcohol More Harmful for People With HIV, Study Suggests
Posted 9 Feb 2016 by Drugs.com
MONDAY, Feb. 8, 2016 – Drinking alcohol may be more dangerous for people infected with HIV, a new study suggests. The effects of alcohol appear to be more pronounced for those with the virus that causes AIDS, even when the virus is suppressed with modern antiretroviral treatment (ART), the Yale University researchers reported. They noted that HIV patients who have just one or two drinks a day are at greater risk for death or alcohol-related health issues. The study involved patients treated by the U.S. Department of Veterans Affairs between 2008 and 2012. There were more than 18,000 HIV-positive patients and over 42,000 people not infected with the virus. The researchers investigated the link between drinking alcohol, death and other health issues the patients developed. They found the patients with HIV who drank even moderate amounts of alcohol were more likely to develop ... Read more
Related support groups: HIV Infection, Alcohol Dependence, Tamiflu, Pre-Exposure Prophylaxis, Alcoholism, Incivek, Hangover, Baraclude, Victrelis, Oseltamivir, Viread, Kaletra, Tenofovir, Norvir, Entecavir, Telaprevir, Lamivudine, Boceprevir, Nevirapine, Prezista
Ask a Question
Further Information
Related Condition Support Groups
HIV Infection, Nonoccupational Exposure, Occupational Exposure


text:
I plan on going to StarFest as I was assured there would be guests from Star wars this year. But concrete plans are still up in the air.
I recieved a few Vintage SW figures in the mail. Havnt seen anything new in stores. BUT! I did find General Windu's Squadron Battlepackat Target for only $4.98! It was the only one I could find unfortunatly.

subset: commoncrawl


text:
Anybody speak Huttese? Anybody?
Sorry to get everyone all worked up, but, thats all the information I seen at fbtb.com. This little bit of news was posted 9-4. Does anyone know if this was just someone pulling evetybodies chains, or is there some truth to it? And does anyone know when we can expect to see the new sets? Will it be for the holidays or in May?


text:
Late last year it looked as though only one New Zealander, Fabian Coulthard, would be racing in the V8 Supercars.
Four-time Bathurst winner Greg Murphy was without a full-time seat and had been signed by the Holden Racing Team only as an endurance driver with Garth Tander.
Added to that, Shane van Gisbergen had become disenchanted with the category and left Stone Brothers Racing.
The first good news came through when it was announced that Gary Rogers Racing had signed 19-year-old Kiwi Scott McLaughlin for the main game after his wins in the Development Series and the inaugural New Zealand V8 SuperTourers series.
"It's great I can continue with my relationship with Fujitsu who have backed me since my karting days when I was 15," said McLaughlin.
"To be able to drive my first V8 Supercar season with them is a big thing for me.
"Seeing my name on the V8SC is really great and I have my crew to work with and I can't wait for the weekend."
Then not long after McLaughlin's announcement came news that after a couple of months back on Kiwi soil Van Gisbergen had his V8 mojo back and had signed with V8 Supercars team Tekno Autosport.
This weekend, Dick Johnson Racing announced former A1GP and Porsche Carrera Cup racer Kiwi Jonny Reid was also to join the main game.
Reid will join Tim Blanchard and pilot the Wilson Security-backed Falcon.
"I'm a very happy chap now that the deal has been signed off. I'm absolutely rapt," said Reid.
"I'm now really looking forward to the year and it's going to be bloody massive."
Dick Johnson Racing has had a rocky journey to the grid this year, and is a bit behind the eight ball with car build and preparation.
On top of that, Reid hasn't even sat in one yet with the engine running.
"I'll be able to snap into race mode straightaway despite it being the first time I will have been on a race track in the car," he said.
"It's right in at the deep end for race one, but it will give us a platform to build on for the rest of the season.
"I'm just delighted to be here and finally make the championship, something I've been working on since 2010."
Clipsal 500 fast facts
*Debut of all-new Car of the Future. This is the first time in Australian Touring Car Championship/V8 Supercars Championship history that an entire field of new cars will be making their racing debut on the one weekend.
*Two new manufacturers join the fray - four Nissan Altimas and three Mercedes-Benz E63 AMGs.
*It will be the first time since the final round of the 1980 ATCC that there has not been a member of the Johnson family competing in an ATCC/V8SC event.
*Four-time Clipsal 500 winner and reigning V8 Supercar champion Jamie Whincup has made the streets of Adelaide his second home.
*Craig Lowndes could create history this weekend. With 89 ATCC/V8SC race wins, he is one short of record-holder Mark Skaife.
*Only three drivers have competed in every Clipsal 500 since it was first held in 1999 - Russell Ingall, Craig Lowndes and Garth Tander.
*Greg Murphy's lack of a full-time drive this year means he will miss the event for the first time.


text:
Deeplinks Blog posts about Analog Hole
UPDATE (9/8/16): An earlier version of this blog post incorrectly suggested that no authorized audio devices or connectors that used the Lightning port existed prior to yesterday's announcement. It also implied that the only way to achieve lossless sound quality on an iPhone was through a wired connection, which was also incorrect. We've edited the post accordingly.
It's the dawn of a new year. From our perch on the frontier of electronic civil liberties, EFF has collected a list of a dozen important trends in law, technology and business that we think will play a significant role in shaping online rights in 2010.
In December, we'll revisit this post and see how it all worked out.
1. Attacks on Cryptography: New Avenues for Intercepting Communications
In 2010, several problems with cryptography implementations should come to the fore, showing that even encrypted communications aren't as safe as users expect. Two of the most significant problems we expect concern cellphone security and web browser security.
Digital Video Recorders, once considered a mortal threat by the entertainment industry, have now become its new best friend. It's just the latest example of how the industry's constant warnings of the dangers of "piracy" frequently turn out to be baseless hysteria.
Remember 2001? Digital Video Recorders ("DVRs") like TiVo and ReplayTV were poised to win mainstream adoption, allowing consumers to fast-forward past advertisements more easily than before. In response, the entertainment industry behaved predictably — it freaked out and filed a bunch of lawsuits.
As Blu-ray.com reports, the AACS licensing authority has released the "Final Adopter Agreement" it plans to enforce against consumer electronics companies that make BluRay players (and any other AACS devices that come along). Buried inside that 188 page document is a plan to eliminate analog video... forever. BluRay device makers will have to restrict analog outputs to low resolution first:
188.8.131.52 Analog Sunset – 2010. With the exception of Existing Models,
any Licensed Player manufactured after December 31, 2010 shall
limit analog video outputs for Decrypted AACS Content to SD
Interlace Modes [composite video, s-video, 480i component video and 576i video] only.
On the last day of 2013, analog outputs will be banned on BluRay players:
While the Senate was standing up for civil liberties, the House was handing out a Christmas gift to Hollywood. For digital consumers and innovators, however, it looks to be a nasty stocking-filler.
Representatives Sensenbrenner and Conyers have introduced H.R. 4569, the "Digital Transition Content Security Act of 2005," a.k.a. the return of the MPAA's "Plugging the Analog Hole" scheme, which is itself just a variant on the dreaded "Hollings Bill" introduced back in 2002.
The new bill is a rehash of the one we first mentioned on Halloween. It would impose strict legal controls on any video analog to digital (A/D) convertors "manufacture[d], imported or otherwise traffic[ed]" in the United States.
Subscribe to EFF Updates
Deeplinks Archives
Deeplinks Topics
- Fair Use and Intellectual Property: Defending the Balance
- Free Speech
- Innovation
- UK Investigatory Powers Bill
- International
- Know Your Rights
- Privacy
- Trade Agreements and Digital Rights
- Security
- State-Sponsored Malware
- Abortion Reporting
- Analog Hole
- Anonymity
- Anti-Counterfeiting Trade Agreement
- Artificial Intelligence & Machine Learning
- Biometrics
- Bloggers' Rights
- Border Searches
- Broadcast Flag
- Broadcasting Treaty
- Cell Tracking
- Coders' Rights Project
- Computer Fraud And Abuse Act Reform
- Content Blocking
- Copyright Trolls
- Council of Europe
- Cyber Security Legislation
- CyberSLAPP
- Defend Your Right to Repair!
- Development Agenda
- Digital Books
- Digital Radio
- Digital Video
- DMCA Rulemaking
- Do Not Track
- E-Voting Rights
- EFF Europe
- Electronic Frontier Alliance
- Encrypting the Web
- Export Controls
- Eyes, Ears & Nodes Podcast
- FAQs for Lodsys Targets
- File Sharing
- Fixing Copyright? The 2013-2016 Copyright Review Process
- Genetic Information Privacy
- Government Hacking and Subversion of Digital Security
- Hollywood v. DVD
- How Patents Hinder Innovation (Graphic)
- International Privacy Standards
- Internet Governance Forum
- Law Enforcement Access
- Legislative Solutions for Patent Reform
- Locational Privacy
- Mandatory Data Retention
- Mandatory National IDs and Biometric Databases
- Mass Surveillance Technologies
- Medical Privacy
- Mobile devices
- National Security and Medical Information
- National Security Letters
- Net Neutrality
- No Downtime for Free Speech
- NSA Spying
- Offline : Imprisoned Bloggers and Technologists
- Online Behavioral Tracking
- Open Access
- Open Wireless
- Patent Busting Project
- Patent Trolls
- Patents
- PATRIOT Act
- Pen Trap
- Policy Analysis
- Printers
- Public Health Reporting and Hospital Discharge Data
- Reading Accessibility
- Real ID
- Reclaim Invention
- Search Engines
- Search Incident to Arrest
- Section 230 of the Communications Decency Act
- Shadow Regulation
- Social Networks
- SOPA/PIPA: Internet Blacklist Legislation
- Student Privacy
- Stupid Patent of the Month
- Surveillance and Human Rights
- Surveillance Drones
- Terms Of (Ab)Use
- Test Your ISP
- The "Six Strikes" Copyright Surveillance Machine
- The Global Network Initiative
- The Law and Medical Privacy
- TPP's Copyright Trap
- Trans-Pacific Partnership Agreement
- Travel Screening
- Trusted Computing
- Video Games
- Wikileaks
- Transparency
- Uncategorized


text:
Hurricane News, November 17, 2010
The fall harvest for the community for years gone by included cotton with the T. J. Hale Gin being a hub of activity at the intersection of Hwy. 346 and Thaxton Road. Recently as I drove through the "Nation" at the old "Rabbit Ranch" area there were fields of sweet potatoes being harvested. The south side of the community is also known as "Who'd A Thought It."
A special family and community effort for a memorial service is planned for DEC. 5 at the Shady Grove Cemetery for Oscar Trannie Baker, U.S. Navy, WWII, who was lost at sea. A veteran's marker will be placed as well as Dr. Bill Baker of Clinton presiding as the guest speaker for the service. Trannie was a graduate of Hurricane High School of the Class of 1943 and the son of the late Dunbar and Pearl(Buchanan)Baker of the community. Let's help honor this serviceman. For additional information, call Shelia Owen at 489-1941.
Union Nazarene Church is having their Thanksgiving meal on Sunday, Nov. 21. The special guest speaker for the day at 11:00 a.m. is Mr. Don Bradley who is the administrator for the Bradley Institute for Native American students for the New Mexico-Arizona regions Bro. Donnie Carpenter is the host pastor.
The Fall Harvest meal will be held Sunday at noon for the congregation at Hurricane Baptist Church on Nov. 21. Bro. Philip Brock is host pastor. The annual Bible Conference is slated for DEC. 12-15.
Get-well wishes to Bobbie Crouch, Nathan Crouch,Allison Ross, Royce Spears, and to Inez Todd.
Colt and Graden Hooker enjoyed a return deer hunting trip to Fulton County Illinois in early November. The next week Cade Hooker, Phil Warren and Phil Robbins hunted the same area. I enjoyed a call from J. R. Austin of Cave-in-Rock, Illinois, who reported that a good hunting season had started there at Lane Mountain on the Ohio River. Their other land borders the Shawnee National Forest on the Ohio which is a beautiful area reminiscent of the old CCC Road forest that was once in Lafayette County. The ferry is open as it is the main entrance and outlet to this river town.
Zane and Glenda Hale enjoyed a vacation to the Smoky Mountains during the autumn season.
Shelly and Madison Carnes, Beth and Ashley Berryhill and Carolyn Carnes enjoyed a shopping trip to Birmingham as several of the family members had October birth dates to celebrate.
Gracie Warren celebrated her sixth birthday on Nov. 9 with a party hosted by her parents Phil and Stephenie
Guide and Don Browning hunted in Madison County with Jon Lacy and Evan Browning this past weekend. Guide Browning celebrated his 19th birthday on Nov. 15. Guide is a freshman at ICC, and Evan is a student at MSU. They are the grandsons of Emily Browning of Germantown, Tenn., and of the late Lacy Browning of Ecru.
Susan and Braxton Hooker attended the Veteran's Day program at the Pontotoc Court Square on Nov. 11 as representatives of the family of the late Warren Norwood who served with the Occupational Forces in Japan, WWII.
Cap and Lou Gaston hosted a birthday dinner for their daughter, Susanne Wade and family, Barney, Karlie, and Clay Russell Wade, of Calhoun City on Nov. 12. A special guest was Marie(Morris)Russell of Union, one of our community's nonagenarians that participate in community events. Clay Russell Wade is a very athletic young man as he plays a variety of sports as the season's change. His grandfather, Cap Gaston, is a former coach and retired educator that enjoys his success.
Congratulations to Faye(Graham)Dillard who will be inducted into the Mississippi Junior College Hall of Fame in Jackson in April for her basketball career at Holmes Junior College from 1950-2.
Lonnie Hale and Generra Brinkley of Memphis, and Onis Bramlett visited with Roy and Faye Dillard on Nov. 13. Uncle Roy got a good report from the oncology doctor on Friday. He enjoyed a phone call from Sen. Roger Wicker on Tuesday who called with get-well wishes.
Sympathy is extended to the family of Doyle Lamar Russell, retired Vice-Chancellor of Administration at the University of Mississippi, as he and his late wife, Melba Jean(Waldrop)Russell had built a new home at the Kendal Russell home place in Hurricane and had enjoyed ten years of their retirement here. He was the top scholar of the Class of 1947 at Hurricane High and continued his education at the University of Mississippi thus beginning his successful career at Ole Miss. Among those attending the services at Sand Springs Church and Cemetery from out of town include the following: His daughter, Angela(Jim)Browning and family; Dr. Richard(Jackie)Russell, all of New Albany; Dr, Stanley Russell of Jackson; and Jeannette(Russell)Jarrett, Memphis;Larry and Pam Russell, Pontotoc.
Sympathy is extended to the family of Toy Lamar Rutledge of Clarinda, Iowa who was the son of Bro. Wayne and Ila(Gregory)Rutledge of the community.
Sympathy is extended to the family of Madge Joyner of Robbs who was the great-grandmother of Eric(Charley)Conlee.
(Community Yesteryears)On November 10, 1935 a plane crash killed three young men from the community:Lamon Graham, Henry Graham, and Bud Warren, all of Sand Springs, as well as Dean Falkner, the younger brother of author William Faulkner of Oxford. Ironically, a wing fell off the plane and landed near the future grave sites of the community residents and crashed near the home of Henry Graham, a short distance away. Several thousand people flooded the community after the news of the crash as well as for the funeral for the local men whose services were held outside the Sand Springs Church. This account can be found in Joseph Blotner's Faulkner as well as the Commercial Appeal.
About Chris Elkins
- East Union stuns Mantachie; wins fast-pitch division title April 20, 2017
- Hawks fall to Lions in extra innings in 1A series April 22, 2017
- Suggs shackles the Bulldogs on one-hitter April 22, 2017
- West Union wins series game one over Houlka April 21, 2017
- Cavender leads Lady Bulldogs to win over Ripley April 21, 2017
- West Union takes game one of series in battle of Lady Eagles April 25, 2017
- Hawks fall to Lions in extra innings in 1A series April 22, 2017
- Suggs shackles the Bulldogs on one-hitter April 22, 2017
- West Union wins series game one over Houlka April 21, 2017
- Cavender leads Lady Bulldogs to win over Ripley April 21, 2017
- Myke Britt: KHM309...Whassa matter? CYBER CAT GOT YOUR TONGUE?...
- Myke Britt: KHM...Thank God we have one president for ALL OF A...
- KHM309: A quick Google search has revealed that you're an...
- Myke Britt: KHM, you lost and AMERICA WON.. Either join AL SHA...
- Myke Britt: I lived in Mississippi so be very careful about ac...
Subscribe to Blog via Email
Recent Posts
Recent Comments
- Myke Britt on No rigged election here
- Myke Britt on No rigged election here
- KHM309 on No rigged election here
- Myke Britt on No rigged election here
- Myke Britt on No rigged election here


text:
By Ben Levisohn
Today's earnings report was no jewel in Ruby Tuesday's (RT) crown.
Ruby Tuesday's has plunged 15% to $6.50 in after-hours trading after the struggling restaurant company reported earnings that missed forecasts by a wide margin.
The restaurant company reported a loss of 36 cents a share,
well below missing forecasts for a 5 cent loss. Sales, meanwhile, came in at $289.7 million, below forecasts for $298 million. Same-store sales fell 11.4% at company-owned Ruby Tuesday restaurants, and dropped 8.4% at franchises.
Ruby Tuesday gained 4.3% today after a B. Riley report said the company might be at trough earnings. Oops.


text:
The mortgage belt and taxpayers have been the main winners in a $5.7 billion rise in households' collective income, after tax and inflation, since the recession, Westpac economists say.
It represents a 5.6 per cent increase over the four years to March 2012, or an average of 1.4 per cent a year.
"This is a major step down from the stellar income growth of the mid-2000s, but is not too different from the growth experienced over the 1990s and early 2000s," Westpac economist Nathan Penny said.
"The increase in household incomes is effectively thanks to the Government, via $6.3 billion worth of tax cuts and $2.7 billion worth of welfare benefit payments."
Increases in wages, salaries and farm incomes made small but positive contributions.
"In contrast, income from capital dived. Income from businesses (private company profits, dividends and small businesses other than farms) fell $3.3 billion, while interest received by households fell $2.7 billion."
Most of the $2.7 billion increase in transfer payments from the Government arose from an additional 70,000 becoming eligible for New Zealand Superannuation, although the numbers on the unemployment and domestic purposes benefits, and drawing accommodation supplement, also increased.
"Interest rate falls have redistributed aggregate household income from savers to borrowers," Penny said.
"Interest payments fell by $3.3 billion, more than offsetting the $2.7 billion fall in interest received."
The net difference, $600 million, reflected the fact that New Zealand households have borrowed more than they saved, as well as the different maturity profile of household deposits and loans.
Looking forward, Westpac expects rising interest rates from late this year will cramp the mortgage belt's style over the next few years, though that will be roughly matched initially by higher incomes for savers.
Meanwhile, as the Government is committed to returning to a budget surplus, its activities will subtract from household incomes over the next few years.
Penny said: "At the same time, insurance money will fund much of the Canterbury rebuild, boosting GDP growth and household incomes more generally."


text:
Web Stories
'Apprentice' winner Kelly Perdew to speak, May 27
Posted May 25, 2005; 10:08 a.m.
Kelly Perdew, winner of the second season of television's "The
Apprentice," will speak at the Princeton Entrepreneurs' Network's sixth
annual Conference on Entrepreneurship Friday, May 27.
Perdew, now executive vice president of Trump Ice, will deliver the keynote address at the conference at 1:45 p.m. in the Friend Center.
Perdew has started or been involved with entrepreneurial companies since his days as a graduate student at the University of California-Los Angeles law and business schools. He will speak on starting a business, potential pitfalls and good business management. He also will discuss his role with the Trump organization and his experience on Donald Trump's popular reality television show "The Apprentice."
The speech is open to the public; admittance at the door is $20.
The full-day conference encompasses a business plan competition judged by successful venture capitalists and entrepreneurs and panels and workshops on effectively running a business. It is cosponsored by the School of Engineering and Applied Science and the Bendheim Center for Finance.
The Princeton Entrepreneurs' Network is devoted to facilitating the founding, funding and support of entrepreneurial companies. It consists of alumni, students, faculty and others connected to the Princeton University community who are entrepreneurs, soon-to-be entrepreneurs, investors, mentors, lawyers, accountants, consultants, other professional service providers and those otherwise interested in entrepreneurship.
For more information on the conference, visit the Princeton Entrepreneurs' Network Web site.


text:
Every organization is comprised of people with different skills and knowledge
The Management program at Eckerd College offers students the unique opportunity to learn the art, the science and the craft of the discipline while gaining a liberal arts education. Because it deals with the integration of people in a common venture, it is deeply embedded in culture. Every organization is comprised of people with different skills and knowledge. It is the manager's job to enable both the organization and each of its members to grow and develop as needs and opportunities change. Finally, neither the quantity of output nor the bottom line is by itself an adequate measure of the performance of the manager and the organization.
The Management discipline consists of two majors: Management and Business Administration. Each is geared to the needs of both the student and society. The Management Major provides the student with skills which can be utilized in any organization, be it for-profit, government or in the social sector. The business administration degree is geared to the student who wants to pursue a career within a for-profit corporate organization and/or a Masters in Business Administration.
Students learn to understand both the people aspects of dealing in business world, such as organizational theories and leadership, while also earning a firm grasp on quantitative concepts and decision sciences. Additionally, experiential learning and internships with various local and national organizations allows the Eckerd student an opportunity to practice the craft of management. Both programs incorporate technology throughout all courses, as demonstrated in the Management Information Systems course and other electives.
Eckerd as a community has a strong emphasis on service learning and the Management Discipline truly applies this by including a service learning community service project as part of the introductory course, Principles of Management and Leadership. The faculty members all have experience in the business world that gives students great insight, which pairs well with the endless opportunities for internships. Our location in Tampa Bay offers access to national banks, corporate headquarters, three professional athletic teams, two major theme parks, and many other opportunities to intern.
Combined, management majors and business administration majors comprise the one of the largest programs of study at Eckerd College, providing many opportunities to interact with students of different perspectives. The department is continuing to grow and foster opportunities for learning and interning abroad. The most recently updated and revised edition of the Fiske Guide to Colleges 2013 recognized Eckerd College as one of two Florida schools with strength in Business. With all of these opportunities and more on the horizon, Eckerd College is a great place to study management and business administration, while integrating the liberal arts philosophy.


text:
UPDATE: Square Enix has pulled the ad, even before this post was published. That has got to be a record. They released a statement, which is posted below.
Video game advertising is creative, I'll admit that much. The latest campaign from Activision/Treyarch promoting Call of Duty: Black Ops 2 called "Surprise" is a stroke of genius. It's great. With that, many other advertising agencies sometimes dig deep in their pockets to create campaigns that transcend traditional advertising; they immerse the subject in advertising that asks you to play along. The latest campaign from Square Enix and its ad firm promoting Hitman: Absolution seeks to immerse its target audience – in cyber-bullying. Continue Reading "Square Enix Promotes Cyber-Bullying With Hitman Ad Campaign" »


text:
Latest Headlines
Five Games In… 157 to Go
Posted on 7 Apr 2011 by Christopher Rowe.
In the NFL, it is customary to critically over-analyze and scrutinize every aspect of the precious 16 games per season. In MLB, having 162 games makes it far easier to let a few slide – especially for the casual fan – and especially in April. Opening Day gets bunting and pomp and circumstance with sellouts across the league and then most fans check out until sometime around Memorial...


text:
Major: Philosophy
Year of Graduation: 1992
Current Job: Business Systems Analyst, Perot Systems, Phoeniz, AZ
At the time this article was written, Becky was working as a Senior Technical Writer. In the past, she has worked in corporate communications, as well as working as a freelance editor and writer for a variety of businesses, newspapers, and magazines. She has also been a reporter for various weekly newspapers.
How did you decide to work in this field?
I have wanted to work as a writer since I was a child. When I got to CSB, there was not a communication major yet. so I started in English. I also wrote the Saint Ben's and St. John's student newspaper and took a semester off to work for a small newspaper in Oklahoma. Though I ended up with a Philosophy degree, I never stopped writing, either paid or volunteer, and it began to pay off after a while. I can't imagine doing anything else.
What is a typical day like for you?
I work in an office two days a week and from home the rest of the week. Depending on deadlines, I spend about the same amount of time researching, writing, and editing. I try not to spend hours staring at my computer screen and still insist on printing off the material I edit. There are also meetings/teleconferences, of course, and when I am home my three-year-old daughter becomes my "co-worker". She "helps" me with her own paper and pencils and likes to hand me books. She can be a challenge when I am pressed for time, but I wouldn't trade the time at home for anything. Since I am developing my own freelance business (iotaunum.com) as well as working for JigsawDirect.com full time, I have to spend some time each week marketing/networking the keep business coming in. This involves lots of email, phone calls and checking certain boards and sites for possible freelance work.
What do you like/dislike about your career?
I like the diversity of topics I get to learn and write about. I also usually get to be creative and work with people who are non-writers. Being part of a creative team is great. I can't think of anything I dislike! With technology today you can do it from anywhere, anytime. I think it is the best!
Are there any specific skills you gained at CSB/SJU that are particularly helpful in your current job?
There is no questioned that I honed my writing skills at CSB even though I didn't major in Communication or English. The more subtle skills have also really served me well, like the critical-thinking and problem-solving skills that I think a liberal arts education nurtures. Most importantly, I developed confidence in my own abilities while at CSB. I believe this confidence is particularly important for women in business. If you don't think you can do the job well, no one else is going to either.
What advice would you give to a student who is interested in a career in writing/editing?
Never stop writing, whether you are being paid for it or graded on it or not. Volunteer to write. If you don't have a paying gig (and even if you do), volunteer for an organization to write for their newsletter or draft press releases or edit their manuals...whatever. Your portfolio is much more important than your resume. Fill it up with good work.
Understand that as a writer it is part of your job to be edited. I am amazed at how many young writers don't understand this aspect of the writing process. You will be required to write in many different styles if you work in the business or non-profit worlds, and good editing will help you understand how you need to write for that particular job. Good editing can only make you a better writer.


text:
Group Booking Terms and Conditions
Because you are making a Group Booking, there are additional Terms and Conditions that apply. Please read them and click 'I Accept' below to continue with your booking
General Group Booking Terms
By making a group reservation through Hostelworld.com you agree to the following terms and conditions as set by Hostelworld.com and as set by the hostel in question.
- In order to make a group reservation on Hostelworld.com it is necessary to pay a deposit. The balance is due directly to the hostel according to their payment conditions.
- The booking deposit is non-refundable.
- Please note that any cancellations must be notified directly to the hostel at least 24 hours in advance of your scheduled arrival date, unless otherwise stated in the hostel's conditions.
- Hostelworld.com are not responsible for changes or amendments to your reservation once it has been processed. All correspondence with regard to changes to your booking need to be dealt with directly with the hostel.
- Cancellations for reservations must be made directly with the hostel and must conform with the individual hostels cancellation policy (see below)
- It is your responsibility to pay the balance of your accommodation cost to the hostel in accordance with their payment conditions (see below). Failure to do so may result in your reservation being cancelled by the hostel.
- Individual hostels may have special booking conditions relating to group stays, please read the hostel booking conditions carefully before making your reservation.
Hostel Specific Terms & Conditions
The remainder of the amount due will be charged to your credit card ???? Should numbers or room selection change, the per person deposit times the number of people who actually travelled will be deducted from the total accommodation charge levvied by the hostel.
The following group types are not accepted by this hostel: Holiday with Friends, Junior / Primary School, High / Secondary School, College / University, Business Trip, Stag/Hen/Bachelor Party, Sports Group, Cultural Group If you have misrepresented the type of group you are booking for, your booking may be cancelled by the hostel.
Any cancellations resulting from agreement to these terms and conditions under false pretences will result in loss of deposit.
Loppuunmyynti on lähellä
Kiinteistövälitys Kuvaus
Tuoreimmat arviot
" Muy buena relación calidad precio. Todo tal cual como se ve en las fotos y aún mejor. La habitación cómoda, sin lujos pero con todo lo necesario, incluso un pequeño refrigerador. Baño completo muy cómodo. Todo muy bien por el precio. La ubicación es muy buena cerca de Termini por lo que es muy accesible por todos los medios, y ademas cerca de muchos lugares turísticos. La atención excelente, y todo muy limpio y ordenado. Volvería sin dudas. Sólo le agragaría el desayuno, aunque sea sencillo, "- Nimetön
Tee varaus matkan varrella uusien Hostelworld-matkapuhelinsovellusten avulla.


text:
Toggle: English / Spanish
Controlling hypertension
If your blood pressure is high, you need to lower it and keep it under control. Your blood pressure reading has 2 numbers. One or both of these numbers can be too high.
The top number is called the systolic blood pressure. This reading is too high if it is 140 or higher.
The bottom number is called the diastolic blood pressure. It is too high if it is 90 or higher.
You are more likely to have high blood pressure as you get older. This is because your blood vessels become stiffer as you age. When that happens, your blood pressure goes up. High blood pressure can lead to stroke, heart attack, heart failure, kidney disease, and early death.
If you have heart or kidney problems, diabetes, or if you had a stroke, your doctor may want your blood pressure to be even lower than people who do not have these conditions.
Many medicines can help you control your blood pressure. Your health care provider will prescribe the best medicine for you. Your health care provider will also monitor your medicines and make changes if you need them.
In addition to taking medicine, you can do many things to help control your blood pressure.
Limit the amount of sodium (salt) you eat. Aim for less than 1,500 mg per day. Limit how much alcohol you drink -- 1 drink a day for women, 2 a day for men.
Eat a heart-healthy diet. Include potassium and fiber, and drink plenty of water. Stay at a healthy body weight. Find a weight-loss program to help you, if you need it.
Exercise regularly -- at least 30 minutes a day of moderate aerobic exercise.
Reduce stress. Try to avoid things that cause you stress. You can also try meditation or yoga.
If you smoke, quit. Find a program that will help you stop.
Your doctor can help you find programs for losing weight, stopping smoking, and exercising. You can also get a referral from your doctor to a dietitian. The dietitian can help you plan a diet that is healthy for you.
Your doctor may ask you to keep track of your blood pressure at home. Make sure you get a good quality, well-fitting home device. It is best to have one with a cuff for your arm and a digital readout. Practice with your health care provider to make sure you are taking your blood pressure correctly.
It is normal for your blood pressure to be different at different times of the day.
It is usually higher when you are at work. It drops slightly when you are at home. It is usually lowest when you are sleeping.
It is normal for your blood pressure to increase suddenly when you wake up. In people with very high blood pressure, this is when they are most at risk for heart attack and stroke.
Your doctor will give you a physical exam and check your blood pressure often. With your doctor, establish a goal for your blood pressure.
If you monitor your blood pressure at home, keep a written record. Bring the results to your clinic visit. Your doctor or nurse may ask you these questions. Having a written record will make them easy to answer:
Call your doctor if your blood pressure goes well above your normal range.
Also call your doctor if you have any of these symptoms:
Gaziano JM, Ridker PM, Libby P. Primary and secondary prevention of coronary heart disease. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Saunders; 2011:chap 49.
Joint National Committee on Detection, Evaluation, and Treatment of Blood Pressure. The seventh report of the joint national committee on detection, evaluation, and treatment of blood pressure. NIH Publication No. 03-5233, May, 2003.
Victor RG. Arterial hypertension. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Saunders; 2011:chap 220.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch)
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2013 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.


text:
When Lisa Jackson, the new Administrator of the Environmental Protection Agency, gave her keynote address at the Aspen Environmental Forum in March, she urged the crowd to work towards a "three-fer."
"Maybe you're worried about what your neighborhood will be once climate change hits you," she said. "Maybe you're worried about where jobs will come from, or whether they will be exported overseas. You might also be worried about national security. However you come to this, we have an answer for you. It's the clean energy economy."
We live in a world where 75 percent to 90 percent of the energy we consume is wasted because of bad design and poor choices. In theory, innovation driven by market forces should work over time to wring more and more efficiency out of our systems, and to eliminate that waste.
Unfortunately, market forces are not perfect. Fuel price volatility makes it hard for entrepreneurs to focus steadily on efficiency innovations and renewable energy sources. Some societal impacts (CO2, for example) are not yet reflected in the cost structures of our businesses. And many of our industries seem as if they were designed specifically to support wasteful practices. These factors combine to create a "roller-coaster effect," with energy policy and commercial practices veering, as President Obama put it, between crisis and trance.
Enter RMI. The RMI team works with dogged determination to reduce—and over decades, eliminate—our dependence on fossil fuels and to speed the profitable transition to a world powered by renewable energy sources very efficiently used. We believe this is the pivotal issue for our generation—even for our species. We stay on the job whether a barrel of oil sells for $150 or $35, and whether or not there is a price on carbon.
RMI's unique "hybrid" structure supports this role. Roughly two-thirds of our funding comes from philanthropic individuals and foundations, helping us to weather economic upheavals and to fund communication through books, films, and the web. The remaining third comes from fees for our consulting and design services—helping to create radically efficient buildings, vehicles, and industrial processes, for example—by which we demonstrate to leaders of vital industries, over and over, that "whole-systems thinking" pays off and that efficiency is the most effective energy solution.
Each of us at RMI has our own personal priorities. Some of us care most about climate change, others about economic opportunities, and still others about national security. But as Amory Lovins likes to say, "We hold and support all of these motivations—and they all lead to the same right outcomes."
The outcome we seek is a world thriving, verdant, and secure, for all, for ever. To get there we need to solve the energy problem. We need to achieve Lisa Jackson's "three-fer." With your help, we believe we can.
Michael Potts is RMI's CEO
--Published April 2009


text:
Web Stories
Video: Student work: 'Sympoh presents "Unleashed"'
Posted February 11, 2011; 05:29 p.m.
Student troupe Sympoh combines a variety of urban dance styles in their spring show, "Unleashed," Feb. 17-19 at the Frist Campus Center theater. Read more.
Video Closed Captions
Hello, ladies. Look at me. Now look at your
man. Now back to me. Sadly, he isn't me, but
if he stopped doing ladies' dances and grabbed
some dope moves, he could dance like me.
Look down. Back up. Where are you? Watching
the b-boy-your-man-could-dance-like do air flares.
What's in your hand? I have it. Two tickets
to that show you long to see. Look again.
The tickets are now beanies. Anything is possible
when your man is a fresh b-boy and not a lady.
I'm upside-down.
Sympoh. Unleashed.


text:
DeFleur recognized for international leadership
Binghamton University President Lois B. DeFleur has been selected by the National Association of State Universities and Land-Grant Colleges (NASULGC) Commission on International Programs to receive the 2007 Michael P. Malone International Leadership Award.
The highly competitive award, established in 2000 to provide national recognition for outstanding contributions that further international education of state and land-grant institutions, is granted to those whose leadership has helped internationalize their campuses.
C. Peter Magrath, senior presidential advisor to the College Board and former Binghamton University president, wrote in a letter of support that Binghamton "…is an international university at its core. The Malone Award recognizes 'international leadership,' and that is what President Lois DeFleur has exemplified with her work at a university that is a model that speaks powerfully to all universities."
Two signature programs that indicate the level of commitment DeFleur and Binghamton University have to internationalization are the Languages Across the Curriculum (LxC) Program and the dual-diploma baccalaureate programs with Turkish universities. In addition, as one who personally believes in the value of learning about other countries and cultures, DeFleur has advocated for courses, research opportunities and extracurricular programs that will prepare Binghamton graduates "to be leaders with a global vision."
Under DeFleur's leadership, the University has developed a variety of study-abroad options that offer opportunities to students not able to taken advantage of semester- or year-long programs; increased the foreign language requirement for graduation; and reinforced the value of internationalization in its strategic plan.
A pilot and the owner of a Comanche 260, DeFleur has flown for more than three decades and served as a Distinguished Visiting Professor at the U.S. Air Force Academy. A graduate of Blackburn College in Illinois, she received the MA degree from Indiana University and the PhD from the University of Illinois.
She is one of three to be honored by the commission this year. The others are Diane Holland Rickerl of South Dakota State University and Richard E. Ewing of Texas A & M University.


text:
You are here:
Answers by Expert:
I've been programming in one form or another since my brother taught me BASIC when I was 6. I've been programing professionally since I was 20, first web development with HTML, JS, DHTML, CSS, etc., then I became a video game developer, writing code in C, C++, C#, SQL, assembly, and various scripting languages. I've even written my own scripting languages, custom designed for the games I was making. I also dabble in Java, PHP, and Perl. I've worked on pretty much every aspect of game development, including graphics, audio, gameplay, tool, UI, input, animation, and physics.
I've been writing C++ code for 12 years, both on my own in my spare time and professionally.
Bachelor of Science in Game Design and Development, Full Sail University, Winter Park, FL
Awards and Honors
Salutatorian and Advanced Achiever Awards at Full Sail; Independent Games Festival Student Showcase winner, 2004; Featured article on Gamasutra about an experimental game developed in 2004
©2017 About.com. All rights reserved.


text:
FDA Clears Lurasidone (Latuda) for Schizophrenia in Adolescents »
"The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of schizophrenia in adolescents aged 13 to 17 years, the company has announc"...
Read the FDA Clears Lurasidone (Latuda) for Schizophrenia in Adolescents article »
Mechanism Of Action
The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. VERSACLOZ also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.
Clozapine demonstrated binding affinity to the following receptors: histamine H1 (Ki 1.1 nM), adrenergic α1A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic α2A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), serotonin 5HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM).
Clozapine causes little or no prolactin elevation.
Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.
In man, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. VERSACLOZ Oral Suspension is bioequivalent to clozapine marketed tablets.
Following oral administration of 100 mg to 800 mg VERSACLOZ, once daily, the average steady-state peak plasma concentration was 275 ng/mL (range: 105-723 ng/mL), occurring at the average of 2.2 hours (range: 1 to 3.5 hours) after dosing. The average minimum concentration at steady-state was 75 ng/mL (range: 11-198 ng/mL).
When VERSACLOZ was administered after a high fat meal there was no effect on the AUCss or Cmin,ss, however Cmax was reduced about 20%, and there was a slight delay in Tmax of 0.5 hour from a median Tmax of 2.0 hours under fasted conditions to 2.5 hours under fed conditions. The decrease in Cmax is not considered clinically relevant. Therefore VERSACLOZ may be taken without regard to meals.
Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important. [see DRUG INTERACTIONS].
Metabolism And Excretion
VERSACLOZ is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. VERSACLOZ is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and N-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4-12 hours), compared to a mean elimination half-life of 12 hours (range: 4-66 hours), after achieving steady-state with 100 mg twice daily dosing.
A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady-state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.
Drug-Drug Interaction Studies
A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about three-fold compared to baseline steady-state concentrations.
Paroxetine, Fluoxetine, and Sertraline
In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
Specific Population Studies
Renal or Hepatic Impairment
No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.
CYP2D6 Poor Metabolizers
A subset (3%-10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.
Clinical Studies
Treatment-Resistant Schizophrenia
The efficacy of clozapine in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions - Severity Scale score of at least 4 (moderately ill).
In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with clozapine (N=126) or chlorpromazine (N=142).
The maximum daily clozapine dose was 900 mg; the mean daily dose was > 600 mg). The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was > 1200 mg.
The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of ≤ 3 (mildly ill), or (2) a BPRS score of ≤ 35, at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of the clozapine group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p < 0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p < 0.001 in each analysis).
Recurrent Suicidal Behavior In Schizophrenia Or Schizoaffective Disorder
The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT™, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine (Clozaril®) versus olanzapine (Zyprexa®, a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met one of the following criteria:
- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.
Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200-900 mg/day for clozapine and 5-20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.
The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by "much worsening" or "very much worsening" from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data.
A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as "treatment-resistant" at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range: 18-69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of "other" races.
Patients treated with clozapine had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine.
The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).
Figure 1: Cumulative Probability of a Significant
Suicide Attempt or Hospitalization to Prevent Suicide in Patients with
Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality
Last reviewed on RxList: 3/13/2017
This monograph has been modified to include the generic and brand name in many instances.
Versacloz FDA Prescribing Information
Additional Versacloz Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Emotional Wellness
Get tips on therapy and treatment.


text:
PJCC Staff Profile
PJCC Personal Trainer Karen Pinckard boasts a credential that isn't found on many resumes: she's a member of the Seven Continents Club, an elite travel club that recognizes runners who have either completed or aspire to complete marathons on all seven continents: North America, South America, Europe, Asia, Africa, Oceania, and Antarctica. Only a handful of women worldwide have achieved this goal and Karen is determined to join them. She is simultaneously aiming to complete seven half and seven full marathons on each continent, averaging at least Continue reading


text:
You are here
Princess Tea Parties
Date & Time
Monday, February 18, 2013 (All day)
Event Details
You're invited to a party--a tea party, that is! Residents of the kingdom of Charleston, enjoy a day of treats, crafts, story time, playtime at the Children's Museum of the Lowcountry, and, of course, an hour-long tea party with the princess of your choice. Be sure not to miss the Happily Ever After Parade or your fairytale goodie bag on the way home. Children's Museum of the Lowcountry, 25 Ann St. Monday, all day. $30, $25 members. (843)853-8962, www.explorecml.org.


text:
Braskem official highlights expansion potential in MexicoComments Email Print
GUANAJUATO, MEXICO (Oct. 11, 1:30 p.m. ET) — Brazilian giant Braskem SA may build its second petrochemical complex on Mexico's Gulf Coast within a decade, according to a senior company official.
Braskem, Latin America's largest petrochemical company, owns 65 percent of a joint venture that is constructing a petrochemical complex, including an ethylene cracker and three polymerization plants, in Coatzacoalcos, Veracruz state, in the Gulf of Mexico.
Mexican petrochemical company Grupo Idesa SA de CV is Braskem's partner in a project scheduled to go on stream in 2015. Idesa owns the joint venture's remaining 35 percent.
"We believe this project could be the first of others" in Mexico, Cleantho Leite Filho, Braskem Idesa's commercial and business development director, told a plastics industry conference in late September.
"We know a country like Mexico will present many other opportunities. We think that if Mexico continues [to grow] like this, in the next five, seven, 10 years we could build another plant in the Gulf of Mexico."
Braskem, headquartered in São Paulo, is also "considering other projects in Bolivia, Peru and Venezuela," he added, without giving details as to what they might be.
The Braskem-Idesa joint venture, known as Ethylene XXI, was formalized in March, 2010. Braskem's investment in it is $3.3 billion, Leite said. The cracker will produce 2.3 billion pounds of ethylene per year, he said, while there will be two high density and one low density polyethylene plants at the complex, where the flattening and preparation of the land is "90 percent finished."
"We are starting pre-marketing operations," the Brazilian official added, explaining that that included "testing clients" and "improving our knowledge of the Mexican market."
Ethylene XXI "represents the reactivation" of the petrochemicals industry in Mexico, Idesa, Mexico's fifth largest petrochemicals company, with sales in 2011 of $625 million, according to Leite, said in a statement in 2010.
"One of the most relevant positive effects [of the complex] is that Mexico will be able to substitute the importation of polyethylene worth approximately $2 billion a year.
"It will have a strong impact on Mexico's trade balance, in addition to creating 6,800 jobs during the complex's construction and about another 800 permanent jobs at the complex, once work is finished."
Leite was a speaker at the two-day convention of Mexico's plastics industry association, Anipac (Asociación Nacional de Industrias del Plástico AC).


text:
Badr Hari Has Lost 23kg In Prison, Denied Parole
- Written by Rian Scalia
The Badr Hari saga continues, as now he's making more news in the Netherlands while continuing to be in prison. Hari was initially released from prison to await trial, but found himself back in when he violated the terms of his release by contacting witnesses and going to a restaurant.
Today, news got out via Badr Hari's lawyer in his request for Hari to be released again that Hari has lost 23kg (50.5lbs) so far since his original stint in prison, also saying that he had become very depressed in the process. Hari's lawyer was trying to get him out of prison for the holidays.
The request for parole was rejected, with the court saying that no new arguments were presented and that releasing Hari would be against the interest of society.
The main case against Badr Hari is the assault on Koen Everink on July 8, where Everink was badly beaten and had his ankle stomped on so hard that is was severely damaged. Everink is now able to walk, but doctors say he will never be able to play sports or run again.
In short, there's a reason we took Badri Hari off the LiverKick rankings. He won't be fighting any time in the near future because of his prison stint, with trial upcoming in January. To add to that, he's clearly in no shape to fight, having lost such a significant amount of weight. [source]


text:
Hip Pointers
A hip pointer is a bruise to the upper part of your hip. Many muscles, including abdominal muscles, attach at this site. A hip pointer can involve injury to bone and soft tissue.
Hip pointers are caused by a direct blow to the bony part of the pelvis. This commonly occurs in when the pelvis comes into contact with a hard object, like a helmut or the boards.. It can also occur by taking a hard fall onto the hip.
A hip pointer is a bruise to the upper part of your hip. Many muscles, including abdominal muscles, attach at this site. A hip pointer can involve injury to bone and soft tissue.
Hip Bone and Local Musculature The iliac crest is the top curve of the pelvis toward the front of the body. Copyright © Nucleus Medical Media, Inc.
Your doctor will ask about your symptoms and medical history. A physical exam will be done. You may be referred to specialist. An orthopedist focuses on bones and joints. A sports medicine physician focuses on sport-related injuries.
Images may need to be taken of structures inside your body. This can be done with
Hip pointers occur through direct blows to the affected area. This is often accidental. As a result, not all hip pointers can be prevented. However, make sure to wear proper sports equipment and padding to decrease your chance of any injury.
Risk Factors
Participating in contact sports increases your chance of developing a hip pointer. Football players and hockey players are especially at risk. Hip pointers are also more common while playing basketball and soccer.
Symptoms of a hip pointer include:
- Severe pain
- Tenderness
- Pain with activity
- Swelling
- Bruising
- Soreness
- Muscle spasms
- Decreased range of motion
Hip pointers are treated with:
- Rest—this may include the use of crutches to move around
- Ice
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- For severe pain, some athletes may receive an injection of a numbing medicine and/or steroid directly into the hip
- Physical therapy to help you regain mobility and build muscle strength
It may take several weeks to heal and for normal movement to return. Check with your doctor about a timeline to return to normal activities. You may be able to return to activity as soon as you feel you are able.


text:
wingo just patched a pretty interesting issue I discovered in Guile's psyntax implementation. Guile uses a modified version of the expander that's module aware, so that lookups and bindings are done -- and hygiene is maintained -- with respect to module eval closures. Top-level definition forms, for example, such as `define' or `define-syntax', create bindings in whatever Guile thinks the "current" module is.
This works great, but there's a wrinkle added by the fact that the expansion process can change the current module. `define-module', for example, does this, by way of an `eval-when' -- after creating a new module, the modules system makes it current, so that if you've got a sequence of expressions like:
(define-module (foo))...then `foo', `bar', and `baz' will be visible to `(foo)' and not to whatever module was current when you called `define-module'. The issue I found involved a slight modification to this pattern, wrapping everything in a `begin' form:
(define foo 'foo) (define bar 'bar) (define baz 'baz)
(begin (define-module (foo)) (define-foo 'foo) ...)Semantically, this should be equivalent to the first form -- at the top level, `begin' splices its contents into the surrounding code as if it weren't even there, enabling you to produce multi-expression, uh, expressions, even in contexts where you're only allowed to produce one, like in the syntax transformer I was writing. But what I was seeing was that my definitions weren't creating bindings in the modules I'd placed them "within" -- particularly hard to troubleshoot when it came syntax definition, since the expander just allowed unbound custom syntax expressions to pass through to the evaluator, assuming they were procedure applications.
The root cause was that Guile didn't anticipate changes to the current module during the expansion of a single top-level form -- so the first form I described would be fine, since the expander would be re-initialized with the current module for each expression; but the second form would only check the current module once, for the `begin', and not after any of the expressions inside it. After Andy's patch, the part of the expander that handles top-level `begin' forms (`chi-top-sequence') checks the current module after each expression in the sequence to see if it's changed and updates the expansion environment appropriately.
All of the above has allowed me to make a fair bit of headway on the R6RS front. A while back I'd gotten started on implementations of the R6RS "standard libraries" and started merging them (along with test suites as appropriate) into Guile's module set (see the wip-r6rs-libraries branch), but I'd had to stop because of the difficulties caused by the issue above (which took me a very long time to isolate and properly articulate). Now I can start again!


text:
New Pediatric Cardiac Imaging and Intervention Center in Washington, D.C. »
"A new state-of-the-art facility dedicated to pediatric cardiac imaging and intervention, co-established by the National Institutes of Health and Children's National Medical Center, was opened with a special dedication ceremony today. The new faci"...
Read the New Pediatric Cardiac Imaging and Intervention Center in Washington, D.C. article »
Nitrostat Patient Information including If I Miss a Dose
In this Article
- What is nitroglycerin (Nitrostat)?
- What are the possible side effects of nitroglycerin (Nitrostat)?
- What is the most important information I should know about nitroglycerin (Nitrostat)?
- What should I discuss with my healthcare provider before taking nitroglycerin (Nitrostat)?
- How should I take nitroglycerin (Nitrostat)?
- What happens if I miss a dose (Nitrostat)?
- What happens if I overdose (Nitrostat)?
- What should I avoid while taking nitroglycerin (Nitrostat)?
- What other drugs will affect nitroglycerin (Nitrostat)?
- Where can I get more information?
What happens if I miss a dose (Nitrostat)?
Since nitroglycerin is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if your next dose is less than 2 hours away. Do not take extra medicine to make up the missed dose.
What happens if I overdose (Nitrostat)?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of nitroglycerin can be fatal.
Overdose symptoms may include a severe throbbing headache, confusion, fever, fast or pounding heartbeats, dizziness, vision problems, nausea, vomiting, bloody diarrhea, trouble breathing, cold or clammy skin, feeling light-headed, fainting, and seizures.
What should I avoid while taking nitroglycerin (Nitrostat)?
Nitroglycerin can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.
Avoid drinking alcohol. It can increase some of the side effects of nitroglycerin, such as dizziness, drowsiness, feeling light-headed, or fainting.
What other drugs will affect nitroglycerin (Nitrostat)?
Many drugs can interact with nitroglycerin. Below is just a partial list. Tell your doctor if you are using:
- alteplase (Activase);
- aspirin or heparin;
- bladder or urinary medications such as oxybutynin (Ditropan) or tolterodine (Detrol);
- blood pressure medication;
- bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva);
- dihydroergotamine (D.H.E. 45, Migranal) or ergotamine (Ergomar, Cafergot, and others);
- an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), clomipramine (Anafranil), imipramine (Tofranil), and others;
- a beta-blocker such as atenolol (Tenormin), carvedilol (Coreg), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), and others;
- a calcium channel blocker such as diltiazem (Tiazac, Cardizem), nifedipine (Procardia), nimodipine (Nimotop), verapamil (Calan, Covera, Verelan), and others;
- irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Cystospaz, and others), or propantheline (Pro-Banthine);
- any medication that causes dry mouth; or
- medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), haloperidol (Haldol), thioridazine (Mellaril), and others.
This list is not complete and there are many other drugs that can interact with nitroglycerin. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Where can I get more information?
Your pharmacist can provide more information about nitroglycerin.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2013 Cerner Multum, Inc. Version: 12.01. Revision date: 8/12/2011.
Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.
Nitrostat Patient Information in Detail
- What is Nitrostat?
- What are the possible side effects?
- What is the most important information I should know?
- What should I discuss with my healthcare provider before taking?
- How should I take?
Additional Nitrostat Information
Nitrostat - User Reviews
Nitrostat User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Nitrostat sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Heart Health
Get the latest treatment options.


text: The important thing to remember is you are going to being doing this hundreds of times...sit, nick, sit. It's not just 4-5 nicks during a session while you walk figure 8s with the dog at heel. BUT if you've watched the puppy DVD and TC, you probably already knew that!


text:
You are here
Hubee D's serves up fast and fresh down-home eats West of the Ashley
It didn't take long for word to spread that some mighty fine chicken was keeping company with Savannah Highway's Coburg cow. Hubee D's opened in August, offering from-scratch Lowcountry cuisine—including hickory-smoked wings and tenders marinated in buttermilk. The family-friendly menu includes fresh-cut nuggets for the small fries, beer and wine for adults, boiled peanuts for snacking, and sophisticated salads for those being virtuous—or saving room for fried banana pudding.
"We wanted to create an atmosphere reminiscent of a 1950s Southern country store where you'd have a simple but memorable meal," says restaurant cofounder Dana Sinkler. And the funky moniker? Hubee is the name of business partner John Ferguson's '64 Studebaker truck, the eatery's mascot, and D stands for Dana's "deelicious" family recipes.
Local architect Reggie Gibson designed the interior, bringing in craftsman Franz Baichel for the rough-hewn booths and David Boatwright for the mural of an old roadside store. Gil Shuler created a bold logo and vintage visuals for the signage. "We were adamant about using area professionals to bring this restaurant to life," notes Ferguson. And we're betting the homemade results make Hubee D's a hometown landmark.
975 Savannah Hwy.,
(843) 556-0330,


text:
Mickael Pietrus [1]' days in a Celtics [2] uniform may be numbered.
Pietrus is "still open to a return," according to his agent Bill McCandless, but the 30-year-old free agent swingman will not play for the NBA's veteran minimum salary — which, after his nine years in the league, is $1.23 million.
'MP will not play for the veteran's minimum. Period," said McCandless. "It's not happening. That's the beginning, middle and end of that. … He is not a veteran's minimum player. There's no chance he'll ever sign for that."
That leaves the $1.96 million bi-annual exception as the C's only option, but that may not be enough. While Pietrus signed for the $1.22 million minimum after being waived by the Suns in December, the French-speaking Guadeloupean has "a standing offer triple that overseas," his agent said. They've also engaged in serious talks with several NBA teams, including one Monday, "and the money was much more than the veteran minimum."
"I've had the veteran minimum thrown at me like hubcaps," added McCandless. "In this collective bargaining agreement, a component of any player's wishes and desires is the money teams are willing to pay. They're pro athletes. My mother might cry in her beer when Johnny Damon [3] runs away to the Yankees [4], but you and I understand it's a business."
Of course, the Celtics may not be willing to offer their bi-annual exception to Pietrus, who would likely fall behind Paul Pierce [5] and Jeff Green [6] at small forward as well as Avery Bradley [7], Courtney Lee [8] and Jason Terry [9] at shooting guard on the depth chart. Pietrus has also undergone surgical procedures on his right knee each of the past two summers.
"[Celtics president] Danny [Ainge] has done his job," said McCandless. "He's going to assemble the team he wants to, and he's done a good job. My job is to do the best thing I can for my client. …
"I really like [Celtics assistant general manager] Mike Zarren. He's very bright. He and Danny, wading through some very complicated rules, have done an outstanding job."
Still, Pietrus averaged 6.9 points (38.5 FG%, 33.5 3P%, 64.5 FT%) and 3.1 rebounds in 21.9 minutes over 42 games for the Celtics. The 6-foot-6, 215-pound wing has averaged 8.4 points (42.7 FG%, 35.7 3P%, 66.5 FT%) for his career. While his numbers dipped to just 3.5 points (32.9 FG%, 22.2 3P%, 56.3 FT%) and 2.1 boards in the playoffs, his defense against the likes of Joe Johnson [10], Evan Turner [11] and LeBron James [12] proved valuable.
The return of Pietrus would only further solidify the C's revamped depth at the 1-2-3 positions. While he expressed his love for both Kevin Garnett [13] and the Celtics tradition at various points throughout last season, for anybody expecting Pietrus to take a hometown discount to remain in Boston, don't hold your breath.
"He's looking for a team that likes him and respects what he does," his agent said. "If he ends up on a championship or playoff contender, that'll take care of itself. … He's still open to a return. He loved Boston. Everybody knows that. But we're all big boys, and this is a big boy business."


text:
This website uses 'cookies' to give you the best possible user experience. We do not share any of the collected data with third parties.
Using this website means you are OK with this. You can find out more about
how and why we use cookies here
Accept (and close this)


text:
Nasty Game – from Nasty TEES
Category Archives: designer of the month
Wordans is the first custom shirt design company in Canada to print high quality apparel for individual use and wholesale. When we say quality, we mean the best quality! We offer custom apparel made from 100% organic cotton. Wordans offers environmentally friendly and organic t-shirts to print your designs on. If you are not sure what type of shirt you are looking for, be sure to check out our list of the most popular t-shirts.


text:
Results 11 to 11 of 11
Thread: Hello from the East Coast.
12-07-2012, 03:10 AM #11Junior Member Guppy
- Join Date
- Dec 2012
- Posts
- 2
I appreciate all the info, I will keep you all updated on what I get and post picks when I can. If I come across any issues, I know who to contact, thanks all.